Stoke Therapeutics, Inc. (STOK) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Stoke Therapeutics reported revenue of $184.4M, up 404.5% from $36.6M the year before. Net income was -$6.9M (a -3.7% net margin), or -$0.12 per diluted share. Operating margin was -11.2%. Operating activities generated $45.6M of cash, leaving $44.9M of free cash flow. At fiscal year end, Stoke Therapeutics held $418.4M in total assets against $66.0M in total liabilities, including $84.2M of cash and equivalents.
Open the full interactive Stoke Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Stoke Therapeutics Key Stats
| Share Price | $22.50 |
|---|---|
| Market Cap | $1.49B |
| Revenue YoY Growth | +404.5% |
| 52-Week Range | $22.37 – $38.35 |
| Shares Outstanding | 66.0 million (basic, 2026 Q2) |
Stoke Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $12.4M | $8.8M | $36.6M | $184.4M |
| Operating Income | -$53.0M | -$86.1M | -$104.4M | -$114.8M | -$101.4M | -$20.6M |
| Pre-Tax Income | -$52.2M | -$85.8M | -$101.1M | -$104.7M | -$89.0M | -$6.9M |
| Income Tax | — | — | — | — | — | $0 |
| Net Income | -$52.2M | -$85.8M | -$101.1M | -$104.7M | -$89.0M | -$6.9M |
| Diluted EPS | -$1.56 | -$2.34 | -$2.60 | -$2.38 | -$1.65 | -$0.12 |
Stoke Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $10.6M | $1.4M | $6.2M | $9.3M |
| Net Income | -$38.3M | -$57.9M | -$50.0M | -$61.6M |
| Diluted EPS | -$0.65 | -$0.98 | -$0.79 | -$0.93 |
Stoke Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $287.3M | $144.9M | $113.6M | $191.4M | $128.0M | $84.2M |
| Current Assets | $293.9M | $229.2M | $244.1M | $215.3M | $232.8M | $305.7M |
| Total Assets | $297.9M | $238.9M | $256.1M | $228.3M | $271.6M | $418.4M |
| Current Liabilities | $11.4M | $17.1M | $31.4M | $30.8M | $40.1M | $57.9M |
| Total Liabilities | $11.8M | $21.1M | $71.2M | $68.8M | $42.5M | $66.0M |
| Shareholders' Equity | $286.1M | $217.8M | $184.8M | $159.6M | $229.0M | $352.5M |
Stoke Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$42.2M | -$66.9M | -$31.9M | -$81.1M | -$86.9M | $45.6M |
| Cash From Investing | -$1.1M | -$76.4M | -$45.9M | $105.9M | -$107.5M | -$186.8M |
| Cash From Financing | $108.1M | $1.3M | $46.4M | $53.0M | $131.1M | $97.4M |
| Free Cash Flow | -$43.3M | -$68.1M | -$35.8M | -$82.7M | -$87.1M | $44.9M |
Figures from Stoke Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Stoke Therapeutics financials page for every line item.
Stoke Therapeutics Company Profile
| Ticker | STOK |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Bedford, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001623526 |
Frequently Asked Questions
What was Stoke Therapeutics' revenue in fiscal 2025?
Stoke Therapeutics (STOK) reported revenue of $184.4M for fiscal 2025.
What is Stoke Therapeutics' annual revenue history?
Stoke Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $12.4M; 2023: $8.8M; 2024: $36.6M; 2025: $184.4M.
What was Stoke Therapeutics' net income in fiscal 2025?
Stoke Therapeutics reported net income of -$6.9M for fiscal 2025.
What was Stoke Therapeutics' earnings per share (EPS) in fiscal 2025?
Stoke Therapeutics' diluted EPS was -$0.12 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Stoke Therapeutics generate in fiscal 2025?
Stoke Therapeutics generated $44.9M of free cash flow in fiscal 2025.
What was Stoke Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Stoke Therapeutics reported revenue of $9.3M.
How many shares of Stoke Therapeutics are outstanding?
Stoke Therapeutics reported a weighted average of 66.0 million basic shares outstanding in 2026 Q2.
What is Stoke Therapeutics' market cap?
Based on its latest closing price, Stoke Therapeutics (STOK) has a market capitalization of about $1.49B.
When does Stoke Therapeutics' fiscal year end?
Stoke Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Stoke Therapeutics headquartered?
Stoke Therapeutics lists its business address in Bedford, Massachusetts in its SEC filings.